Paul M McKie1, Omar F AbouEzzeddine2, Christopher G Scott3, Ramila Mehta3, Richard J Rodeheffer2, Margaret M Redfield2, John C Burnett2, Allan S Jaffe4. 1. Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Department of Internal Medicine, mckie.paul@mayo.edu. 2. Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Department of Internal Medicine. 3. Division of Biostatistics, Department of Laboratory Medicine and Pathology, and. 4. Division of Cardiovascular Diseases, Department of Internal Medicine, Laboratory Medicine and Pathology, Mayo Clinic and Foundation, Rochester, MN.
Abstract
INTRODUCTION: High-sensitivity cardiac troponin assays have potent prognostic value in stable cardiovascular disease cohorts. Our objective was to assess the prognostic utility of a novel cardiac troponin I (cTnI) high-sensitivity assay, independently and in combination with amino-terminal pro-B-type natriuretic peptide (NT-proBNP), for the future development of heart failure and mortality in the general community. METHODS: A well-characterized community-based cohort of 2042 participants underwent clinical assessment and echocardiographic evaluation. Baseline measurements of cTnI with a high-sensitivity assay and NT-proBNP were obtained in 1843 individuals. Participants were followed for new-onset heart failure and mortality with median (25th, 75th percentile) follow-up of 10.7 (7.9, 11.6) and 12.1 (10.4, 13.0) years, respectively. RESULTS: When measured with a high-sensitivity assay, cTnI greater than the sex-specific 80th percentile was independently predictive of heart failure [hazard ratio 2.56 (95% confidence interval 1.88-3.50), P < 0.001] and mortality [1.91(1.49-2.46), P < 0.001] beyond conventional risk factors in this community-based cohort, with significant increases in the net reclassification improvement for heart failure. The prognostic utility of cTnI measured with a high-sensitivity assay goes beyond NT-proBNP, yet our data suggest that these 2 assays are complementary and most beneficial when evaluated together in identifying at-risk individuals in the community. CONCLUSIONS: Our findings lay the foundation for prospective studies aimed at identification of individuals at high risk by use of a multimarker approach, followed by aggressive prevention strategies to prevent subsequent heart failure.
INTRODUCTION: High-sensitivity cardiac troponin assays have potent prognostic value in stable cardiovascular disease cohorts. Our objective was to assess the prognostic utility of a novel cardiac troponin I (cTnI) high-sensitivity assay, independently and in combination with amino-terminal pro-B-type natriuretic peptide (NT-proBNP), for the future development of heart failure and mortality in the general community. METHODS: A well-characterized community-based cohort of 2042 participants underwent clinical assessment and echocardiographic evaluation. Baseline measurements of cTnI with a high-sensitivity assay and NT-proBNP were obtained in 1843 individuals. Participants were followed for new-onset heart failure and mortality with median (25th, 75th percentile) follow-up of 10.7 (7.9, 11.6) and 12.1 (10.4, 13.0) years, respectively. RESULTS: When measured with a high-sensitivity assay, cTnI greater than the sex-specific 80th percentile was independently predictive of heart failure [hazard ratio 2.56 (95% confidence interval 1.88-3.50), P < 0.001] and mortality [1.91(1.49-2.46), P < 0.001] beyond conventional risk factors in this community-based cohort, with significant increases in the net reclassification improvement for heart failure. The prognostic utility of cTnI measured with a high-sensitivity assay goes beyond NT-proBNP, yet our data suggest that these 2 assays are complementary and most beneficial when evaluated together in identifying at-risk individuals in the community. CONCLUSIONS: Our findings lay the foundation for prospective studies aimed at identification of individuals at high risk by use of a multimarker approach, followed by aggressive prevention strategies to prevent subsequent heart failure.
Authors: Lisa C Costello-Boerrigter; Guido Boerrigter; Margaret M Redfield; Richard J Rodeheffer; Lynn H Urban; Douglas W Mahoney; Steven J Jacobsen; Denise M Heublein; John C Burnett Journal: J Am Coll Cardiol Date: 2006-01-04 Impact factor: 24.094
Authors: Paul M McKie; Denise M Heublein; Christopher G Scott; Mary Lou Gantzer; Ramila A Mehta; Richard J Rodeheffer; Margaret M Redfield; John C Burnett; Allan S Jaffe Journal: Clin Chem Date: 2013-04-16 Impact factor: 8.327
Authors: Torbjørn Omland; Marc A Pfeffer; Scott D Solomon; James A de Lemos; Helge Røsjø; Jūratė Šaltytė Benth; Aldo Maggioni; Michael J Domanski; Jean L Rouleau; Marc S Sabatine; Eugene Braunwald Journal: J Am Coll Cardiol Date: 2013-02-13 Impact factor: 24.094
Authors: David M Leistner; Jens Klotsche; Lars Pieper; Günter K Stalla; Hendrik Lehnert; Sigmund Silber; Winfried März; Hans-Ulrich Wittchen; Andreas M Zeiher Journal: Clin Chem Date: 2011-12-07 Impact factor: 8.327
Authors: Mark Ledwidge; Joseph Gallagher; Carmel Conlon; Elaine Tallon; Eoin O'Connell; Ian Dawkins; Chris Watson; Rory O'Hanlon; Margaret Bermingham; Anil Patle; Mallikarjuna R Badabhagni; Gillian Murtagh; Victor Voon; Leslie Tilson; Michael Barry; Laura McDonald; Brian Maurer; Kenneth McDonald Journal: JAMA Date: 2013-07-03 Impact factor: 56.272
Authors: Thomas J Wang; Kai C Wollert; Martin G Larson; Erin Coglianese; Elizabeth L McCabe; Susan Cheng; Jennifer E Ho; Michael G Fradley; Anahita Ghorbani; Vanessa Xanthakis; Tibor Kempf; Emelia J Benjamin; Daniel Levy; Ramachandran S Vasan; James L Januzzi Journal: Circulation Date: 2012-08-20 Impact factor: 29.690
Authors: Vijay Nambi; Xiaoxi Liu; Lloyd E Chambless; James A de Lemos; Salim S Virani; Sunil Agarwal; Eric Boerwinkle; Ron C Hoogeveen; David Aguilar; Brad C Astor; Pothur R Srinivas; Anita Deswal; Thomas H Mosley; Josef Coresh; Aaron R Folsom; Gerardo Heiss; Christie M Ballantyne Journal: Clin Chem Date: 2013-09-13 Impact factor: 8.327
Authors: Tanja Zeller; Hugh Tunstall-Pedoe; Olli Saarela; Francisco Ojeda; Renate B Schnabel; Tarja Tuovinen; Mark Woodward; Allan Struthers; Maria Hughes; Frank Kee; Veikko Salomaa; Kari Kuulasmaa; Stefan Blankenberg Journal: Eur Heart J Date: 2013-10-08 Impact factor: 29.983
Authors: Stephen L Seliger; Susie N Hong; Robert H Christenson; Richard Kronmal; Lori B Daniels; Joao A C Lima; James A de Lemos; Alain Bertoni; Christopher R deFilippi Journal: Circulation Date: 2017-02-03 Impact factor: 29.690
Authors: Renate B Schnabel; Philipp S Wild; Sandra Wilde; Francisco M Ojeda; Andreas Schulz; Tanja Zeller; Christoph R Sinning; Jan Kunde; Karl J Lackner; Thomas Munzel; Stefan Blankenberg Journal: PLoS One Date: 2014-11-17 Impact factor: 3.240
Authors: Elise D Riley; Priscilla Y Hsue; Eric Vittinghoff; Alan H B Wu; Phillip O Coffin; Peter K Moore; Kara L Lynch Journal: Drug Alcohol Depend Date: 2017-01-19 Impact factor: 4.492